Clinical value of microRNA-130a as a marker of acute liver failure and its involvement in disease development.

Objective: This study was to investigate the clinical value of microRNA (miR)-130a in acute liver failure (ALF).

Methods: ALF patients (n = 120, ALF group) and 106 healthy subjects (control group) were enrolled. Serum was collected to detect alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBIL) by automatic biochemical analyzer, and miR-130a by real-time fluorescence quantitative PCR. According to the Child-Pugh score, ALF patients could be divided into grades A, B, and C, and levels of ALT, AST, TBIL, and miR-130a in each grade were observed. Pearson correlation coefficient method was employed to analyze the correlation between miR-130a and Child-Pugh scores and liver function indices. ALF patients were divided into high-low miR-130a expression groups, and poor prognoses were observed. The influence of miR-130a on prognosis was analyzed by Kaplan-Meier curve, and the prognostic value of miR-130a was analyzed by the ROC curve.

Results: miR-130a, ALT, AST, and TBIL were increased in the ALF group. miR-130a, ALT, AST, and TBIL increased with the increase of the Child-Pugh grade. miR-130a levels were positively correlated with ALT, AST, and TBIL levels. The incidence of poor prognoses was 58.33% in the miR-130a high expression group and 30% in the miR-130a low expression group. The prognosis of the miR-130a low expression group was better than that of the miR-130a high expression group, and miR-130a had predictive value for the prognosis of ALF patients.

Conclusion: miR-130a is increased in ALF, and it has high value for both diagnosis and prognosis in ALF patients, and patients with high levels of miR-130a have a poor prognosis.